JUser: :_load: Unable to load user with ID: 291

Thursday, 05 May 2016 01:00

Clinical Research: Efficacy of kinkeliba in non complicated hypertensive patients

Rate this item
(2 votes)

image seckName: Seck Sidy Mohamed

Hospital / Affiliation: Saint-Louis Regional Hospital/Faculty of Health Sciences - University Gaston Berger

Home Country: Senegal

Host Country: Senegal

Year: 2014

Status of your program: Completed


 Title of the project:

 Efficacy of kinkeliba in non complicated hypertensive patients


Chronic Kidney Injury


Short description of the project or abstract:

Hypertension represents a worldwide public health issue. Combretum micranthum (kinkeliba) and Hibiscus sabdariffa (bissap) are popular beverages in West Africa also widely used in traditional medicine. In vitro studies identified many compounds in kinkeliba leaves and bissap calyx with anti-hypertensive activity but there is few evidence of such effects in clinical practice. The purpose of this study was to assess the clinical efficacy and tolerability of kinkeliba and bissap in non-complicated hypertensive patients.
Patients and methods: A prospective randomized controlled trial was conducted at the University Hospital of Saint-Louis. We enrolled 125 patients aged ≥18 years and diagnosed with systolic blood pressure (SBP) between 140 and 179 mm Hg and/ or diastolic blood pressure (DBP) between 90 and 109 mm Hg and without any visceral complication or prior medication. After signing a free consent form, all enrolled patients were randomly assigned in either group 1 (kinkeliba leaves 380 mg/day) or group 2 (bissap calyx 640 mg/day) or group 3 (ramipril 5 mg/day) during 04 weeks. At day 0 and day 28, investigators collected clinical and biological parameters (blood pressure, glycemia, serum cholesterol, serum creatinine, plasma and urine electrolytes).

Main Outcomes: After 04 weeks of treatment, the SBP in kinkeliba group (n = 42) decreased from 152.4 to 140.6 mm Hg (reduction of 12.2 ± 6.6 mm Hg, p-value <0.001), and the mean DBP from 95.5 to 90.4 (reduction of 5.0 ±3.0, p-value <0.001), whereas mean SBP dropped from 155.5 to 144.2 mm Hg (reduction of 11.2 ±3.3, p-value <0.001) and DBP from 95.4 to 89.4 mm Hg (reduction of 6.0 ±4.7, p-value <0.001) in the bissap group (n=42). In the ramipril group (n =41), the mean SBP changed from 156.2 to 139.5 mm Hg (reduction of 16.7 ± 8.4 mm Hg, p-value <0.001) and the DBP dropped from 93.9 to 87.3 mm Hg (reduction of 6.7 ±3.6, p-value <0.001). The reduction in SBP and DBP were significantly more important in the ramipril group as compared to kinkeliba group (p=0.001) and bissap group (p=0.015). No severe clinical or biological adverse event was reported.

Conclusion: These findings suggest that kinkeliba and bissap are efficient on blood pressure reduction and well tolerated. However, the amplitude of their antihypertensive effects was inferior to the one obtained with ramipril. This small-sized trial can lay the groundwork for future larger studies.


Learning or Research objectives:

The research objectives were to assess clinical efficacy of medicinal plants in non complicated hypertension


Additional Info

  • Year: 2014
  • Status: Completed
  • Partners: ISN only
  • Region: Africa
  • Country: Senegal
  • Topics: CKD
Read 7579 times Last modified on Thursday, 05 May 2016 08:42

Global Operations Center

Avenue des Arts 1-2
1210 Brussels, Belgium
Tel: +32 2 808 04 20
Fax: +32 2 808 4454
Email contact


Americas Operations Center

340 North Avenue 3rd Floor
Cranford, NJ 07016-2496, United States
Tel: +1 567 248 9703
Fax: +1 908 272 7101
Email contact